Safety And Efficacy In Long Term Use Of Lyrica (Regulatory Post Marketing Commitment Plan) (RAINBOW-L)

Viatris

Status: Completed

Conditions: Neuropathic Pain

Treatments: Drug: Pregabalin (Lyrica) capsule

Study type: Observational

Funder types: Industry

Identifiers

NCT01279850

A0081262

Details and patient eligibility

About

The objective of this investigation is to evaluate the safety and efficacy of long term use with Lyrica in medical practice. Also, occurrence of unknown and known adverse drug reactions (ADRs) in subjects treated with Lyrica will be monitored during the survey period, and whether an additional treatment outcome investigation and/or a post-marketing clinical study is required in the future will be determined.

Full description

Patients who fulfill criteria below:

1. Patients who have previously enrolled in A0081261.
2. Patients who have been administered Lyrica for more than 52 weeks.

Enrollment: 891 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients need to be administered by Lyrica for over 52 weeks in order to be enrolled in the surveillance.

Exclusion criteria

• Patients not administered Lyrica.

Trial design

891 participants in 1 patient group

Pregabalin (Lyrica) capsule

Description:

Patients administered "Pregabalin capsule".

Treatment:

Drug: Pregabalin (Lyrica) capsule